Pernod Ricard SA (OTCMKTS:PDRDF – Get Rating) shares traded down 2.7% on Tuesday . The company traded as low as C$207.20 and last traded at C$207.20. 313 shares changed hands during mid-day trading, an increase of 19% from the average session volume of 263 shares. The stock had previously closed at C$213.00.
Analyst Ratings Changes
PDRDF has been the topic of a number of recent analyst reports. Credit Suisse Group upgraded shares of Pernod Ricard from a “neutral” rating to an “outperform” rating in a report on Thursday, December 15th. Deutsche Bank Aktiengesellschaft cut shares of Pernod Ricard from a “hold” rating to a “sell” rating in a research report on Thursday, January 12th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Pernod Ricard from $250.00 to $220.00 and set an “overweight” rating for the company in a research note on Thursday, December 1st. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Pernod Ricard presently has an average rating of “Moderate Buy” and a consensus target price of C$227.83.
Pernod Ricard Stock Down 2.7 %
The business has a 50 day simple moving average of C$205.05 and a 200-day simple moving average of C$192.13.
Pernod Ricard Company Profile
Pernod Ricard SA engages in the manufacture of wines, spirits, and non-alcoholic beverages. The firm offers products under the brands Absolut Vodka, Chivas Regal, Ballantine’s, Beefeater, Jameson, Kahlúa, Malibu, Ricard, Havana Club, Martell, Cognac, The Glenlivet, G.H. Mumm, Perrier-Jouët, Royal Salute, Brancott Estate, Graffigna, Campo Viejo, Jacob’s Creek, Kenwood, Pastis 51, 100 Pipers, ArArAt, Becherovka, Blenders Pride, Clan Campbell, Imperial, Seagram’s Imperial Blue, Olmeca, Passport Scotch, Amaro Ramazzotti, Ruavieja, Royal Stag, Seagram’s Gin, Something Special, Suze, Wiser’s, and Wyborowa.
- Get a free copy of the StockNews.com research report on Pernod Ricard (PDRDF)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for Pernod Ricard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernod Ricard and related companies with MarketBeat.com's FREE daily email newsletter.